Petzer, Verena 
; Tymoszuk, Piotr ; Asshoff, Malte ; Carvalho, Joana ; Papworth, Jonathan ; Deantonio, Cecilia ; Bayliss, Luke ; Wake, Matthew Stephen ; Seifert, Markus ; Brigo, Natascha ; Valente de Souza, Lara ; Hilbe, Richard ; Grubwieser, Philipp ; Demetz, Egon ; Dichtl, Stefanie ; Volani, Chiara ; Berger, Sylvia ; Böhm, Felix ; Hoffmann, Alexander ; Pfeifhofer-Obermair, Christa ; von Raffay, Laura ; Sopper, Sieghart ; Arndt, Stephanie ; Bosserhoff, Anja ; Kautz, Léon ; Perrier, Prunelle ; Nairz, Manfred ; Wolf, Dominik ; Weiss, Guenter ; Germaschewski, Volker ; Theurl, Igor
; Tymoszuk, Piotr ; Asshoff, Malte ; Carvalho, Joana ; Papworth, Jonathan ; Deantonio, Cecilia ; Bayliss, Luke ; Wake, Matthew Stephen ; Seifert, Markus ; Brigo, Natascha ; Valente de Souza, Lara ; Hilbe, Richard ; Grubwieser, Philipp ; Demetz, Egon ; Dichtl, Stefanie ; Volani, Chiara ; Berger, Sylvia ; Böhm, Felix ; Hoffmann, Alexander ; Pfeifhofer-Obermair, Christa ; von Raffay, Laura ; Sopper, Sieghart ; Arndt, Stephanie ; Bosserhoff, Anja ; Kautz, Léon ; Perrier, Prunelle ; Nairz, Manfred ; Wolf, Dominik ; Weiss, Guenter ; Germaschewski, Volker ; Theurl, Igor 
Abstract
Recombinant erythropoietin (EPO) and iron substitution are a standard of care for treatment of anemias associated with chronic inflammation, including anemia of chronic kidney disease. A black box warning for EPO therapy and concerns about negative side effects related to high-dose iron supplementation as well as the significant proportion of patients becoming EPO resistant over time explains the ...
Owner only: item control page
Altmetric